Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Embattled Valeant Shakes Up Executive Team in Strategic Plan to Create a Whole New Company

Valeant Pharmaceuticals International Inc. announced a series of leadership and organizational changes.

Read More »

Florida governor criticizes Washington for lagging in Zika fight

Florida Republican Governor Rick Scott accused the federal government of lagging in providing assistance to combat the spread of the Zika virus in a Miami-area neighborhood, the site of the first U.S. transmission of the virus.

Read More »

Novartis asthma pill shows promise in small trial

The first new asthma pill in decades has produced promising results in a small study, potentially paving the way for another treatment option by the end of the decade.

Read More »

Bristol-Myers’ Opdivo fails lung cancer trial

Bristol-Myers Squibb’s blockbuster Opdivo failed to slow progression of symptoms in previously untreated patients with advanced lung cancer in a late-stage study.

Read More »

Some AACC Scientists Quit the Organization Over Theranos CEO’s High-Profile Speaking Slot

There is continued fallout among scientists and members of the American Association for Clinical Chemistry (AACC) following the presentation of embattled Theranos head Elizabeth Holmes during the annual meeting in Philadelphia.

Read More »

FDA Warns Chinese Drugmaker Over Making False Statements to Regulators

The U.S. Food and Drug Administration has a warning for Chinese company Xiamen Origin Biotech – don’t lie. A January inspection of that company’s facilities in China revealed a number of violations by the company, including a false claim that no drugs were kept on site. However, an FDA inspector saw a room that was used to warehouse relabeled medications, StatNews reported. Inspectors also noted that despite being told that Xiamen Origin Biotech has ceased relabeling drugs in January 2015, one year prior to the FDA inspection, investigators “reviewed a list of exported drugs that showed Xiamen had distributed them until January 2016,” StatNews said.

Read More »

Novo Nordisk cuts forecasts on tough U.S. market

Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.

Read More »

Concomitant medications in clinical trials: Why the stakes are high

Almost every reported concomitant medication has a reason – and many, if not all of these reasons should be reported as adverse events.

Read More »

U.S. panel backs approval of Egalet’s abuse-resistant painkiller

A U.S. advisory panel recommended approval of Egalet Corp.’s long-acting opioid painkiller, Arymo ER, saying it dulls pain and could deter abuse by addicts seeking a quick high.

Read More »

Can a portable device make biotech drugs on demand?

A portable system that produces tiny batches of biotech drugs might one day help get crucial medicines and vaccines to remote villages and war-torn regions where they are desperately needed, scientists hope.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom